Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Non-Current Debt (2019 - 2021)

VYNE Therapeutics' Non-Current Debt history spans 3 years, with the latest figure at $33.3 million for Q1 2021.

  • For Q1 2021, Non-Current Debt rose 1.39% year-over-year to $33.3 million; the TTM value through Mar 2021 reached $33.3 million, up 1.39%, while the annual FY2020 figure was $33.2 million, 1.37% up from the prior year.
  • Non-Current Debt reached $33.3 million in Q1 2021 per VYNE's latest filing, roughly flat from $33.2 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $33.3 million in Q1 2021 to a low of $32.7 million in Q4 2019.
  • Average Non-Current Debt over 3 years is $33.0 million, with a median of $33.0 million recorded in 2020.
  • Peak YoY movement for Non-Current Debt: increased 1.37% in 2020, then rose 1.39% in 2021.
  • A 3-year view of Non-Current Debt shows it stood at $32.7 million in 2019, then increased by 1.37% to $33.2 million in 2020, then increased by 0.3% to $33.3 million in 2021.
  • Per Business Quant, the three most recent readings for VYNE's Non-Current Debt are $33.3 million (Q1 2021), $33.2 million (Q4 2020), and $33.0 million (Q3 2020).